Companies · Other Health Care

TECLens, Inc.

STAMFORD · Other Health Care

Diligence memoA one-page analyst read on TECLens, Inc. — recommendation, valuation, rhythm, risks.
$10.6M
Total raised · real
3
Rounds
2.2×
Latest step-up
Top 24%
Sector rank · raised
Series A
Latest stage · inferred · Thu May 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

TECLens, Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.26× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
  • Within the normal band (126% of peer median) for its niche.
Quiet
  • Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

TECLens, Inc. is one of 5376 Other Health Care companies tracked from STAMFORD. By capital raised it ranks in the upper tier (ahead of 77% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2024
Year incorporated
2024-05-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2017-05-22 Raised $1.2M (real) Modeled valuation $29M (est)$1.2M$29MSeed2017Seed · 2019-02-01 Raised $200K (real) Modeled valuation $5.0M (est)$200K$5.0MSeed2019Series A · 2024-05-30 Raised $4.3M (real) Modeled valuation $21M (est)$4.3M$21MSeries A2024Series A · 2024-05-30 Raised $9.3M (real) Modeled valuation $46M (est)$9.3M$46MSeries A2024+$200K+$4.3M+$9.3MCumulative $15M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.2M · 2017
Seed extension$200K · 2019
Series A$4.3M · 2024
Series A extension$9.3M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$46.1M
Base estimate est.
$11.9M
Conservative case
$101.6M
Upside case
$42.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $28.7M · 2017-05-222017Seed · modeled $5.0M · 2019-02-01Series A · modeled $21.2M · 2024-05-30Series A · modeled $46.1M · 2024-05-302024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
2.1 yr
Elapsed time used
2.1 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
28 mo
Avg between rounds
$1.5M/yr
Capital velocity
9.1 yr
On record since
2017
First round
4
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.4× above median
This company$10.6M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.7× above median
This company$9.3M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 2.1× above median
This company$46.1M
Sector median$22.1M

Raised more than 77% of sector peers (real $). Modeled value above 66% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #73 of 196.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.1M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $141.8M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $124.9M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $122.9M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $118.9M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.6M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.4M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.0M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.6M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.1M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.5M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.3M (est)TECLens, Inc. (this company) Raised $10.6M · modeled $46.1M (est)TECLens, Inc.
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.1M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$141.8M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$124.9M3.41×
Post Acute Recovery, Inc.Series A$14.5M$122.9M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$118.9M3.25×
Etiometry Inc.Series A$15.6M$114.6M3.13×
SafKan, Inc.Series A$13.0M$108.4M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.0M2.78×
Outliers Inc.Series A$13.6M$101.6M2.77×
RevMedica, Inc.Series A$14.2M$101.1M2.76×
Innovoyce LLCSeries A$9.9M$97.5M2.66×
Prixz, Inc.Series A$9.2M$97.3M2.66×
TECLens, Inc. this companySeries A$10.6M$46.1M1.26×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.2M2017-05-22$5.8M$28.7M90%
Seed$200K2019-02-01$1.0M$5.0M90%
Series A$4.3M2024-05-30$19.4M$21.2M90%
Series A$9.3M2024-05-30$42.2M$46.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.2M2017-05-22
    • First recorded raise — entered as Seed.
    • 3 investors on this round.
  2. Seed$200K2019-02-01
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 5.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  3. Series A$4.3M2024-05-30
    • Raised again after 64 mo — slower than the ~14 mo sector norm.
    • Round 21.4× larger than the prior — scaling up.
    • 2 investors on this round.
  4. Series A$9.3M2024-05-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~28mo cadence
$20.1M
Modeled next size est.range $13.1M$32.2M
2.2×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Acker3 other2017-05
Hirak E. Parikh1 other2024-05
David E. Acker2024-05
Deng E. Mao2024-05
Patrick E. Lopath2024-05
Richel E. Liu2024-05
Thomas Alan Dunlap2024-05
Registry & provenance

TECLens, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1708436
SEC CIK
2024
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Responsive Arthroscopy, Inc.Other Health CareSeries A$10.0M$42.6Mnetwork1 shared operator · same sector · same stage
Mixlab, Inc.Other Health CareSeries A$10.6M$39.1Msame sector · same stage
WellAWARE Systems, Inc.Other Health CareSeries A$10.7M$40.4Msame sector · same stage
Exthymic CorpOther Health CareSeries A$10.2M$52.4Msame sector · same stage
TZVECL Holdings, LLCOther Health CareSeries A$11.1M$52.5Msame sector · same stage
Iridex CorpOther Health CareSeries A$10.0M$37.2Msame sector · same stage
LexaGene Life Sciences RD Investors, LLCOther Health CareSeries A$10.0M$53.2Msame sector · same stage
Manuka Performance USA, Inc.Other Health CareSeries A$10.0M$41.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TegoSens, Inc.Other Health CareSeed$35.5M87%
TETmedical, Inc.Other Health CareSeed$17.4M87%
TecTraum, Inc.Other Health CareSeed$36.6M85%
Teckro, Inc.Other Health CareSeries B$366.1M85%
tEMed Holdings LLCOther Health CareSeries A$121.1M85%
Tetricus Inc.Other Health CarePre-Seed$2.7M85%
Tegria Services Group, Inc.Other Health CareSeries A$7.6M84%
Tempmee Hygienists, Inc.Other Health CareSeries A$11.6M83%
Frequently asked
How much funding has TECLens, Inc. raised?
TECLens, Inc. has raised approximately $10.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is TECLens, Inc.'s estimated valuation?
Provath's modeled valuation for TECLens, Inc. is approximately $46.1M (modeled range $11.9M–$101.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is TECLens, Inc. at?
TECLens, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu May 30.
What does TECLens, Inc. do and where is it based?
TECLens, Inc. operates in the Other Health Care sector, based in STAMFORD.
Explore related

See where TECLens, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at TECLens, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.